Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

VANFLYTA 17.7 mg film-coated tablets {equilateral_black_triangle}

Active Ingredient:
quizartinib dihydrochloride
Company:  
Daiichi Sankyo UK Limited See contact details
ATC code: 
L01EX11
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

VANFLYTA - HCP guide: Important information for healthcare professionals about serious risks associated with Vanflyta

{healthcare_pro_orange} For Healthcare Professionals

Important information for healthcare professionals about serious risks associated with Vanflyta

{pdf_link}

Vanflyta (Quizartinib)- Initial- Patient Alert Card

{healthcare_pro_orange} For Healthcare Professionals
A reminder to distribute a patient Card to any patient receiving Vanflyta treatment for the first time or if asked for a new copy

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Daiichi Sankyo UK Limited
Company image
Address
1st Floor, Building 4, Uxbridge Business Park, Sanderson Road, Uxbridge, UB8 1DH, UK
Telephone
+44 (0) 800 028 5122
Medical Information Direct Line
+44 (0) 800 028 5122
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0) 800 028 5122
Out of Hours Telephone
+44 (0) 800 028 5122